- Email:
Huntington's Disease Modeling Service
Introduction
Huntington's disease is a progressive neurodegenerative disorder caused by CAG repeat expansion in the HTT gene. Human iPSC models are essential for studying human-specific disease mechanisms. Creative Biolabs provides high-fidelity Huntington's disease modeling services using iPSC-derived 3D organoids, AAV gene therapy platforms, and CRISPR-Cas9 editing. The service supports patient-specific model construction and delivers quantitative data on HTT aggregation, mitochondrial function, and neuronal activity, enabling reliable therapeutic validation and accelerated drug development.
Discover How We Can Help - Request a Consultation →
Huntington's Disease Modeling Service
Huntington's disease (HD) is an inherited neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the HTT gene, leading to mutant huntingtin protein aggregation, striatal and cortical neurodegeneration, motor dysfunction, and cognitive decline.
Our HD Modeling Service uses human iPSC-derived 3D neural/striatal organoids, gene-edited cell models, and transgenic animal systems to faithfully recapitulate key pathological and functional features of HD.
Fig.1 The structure of the HTT gene and the mutations that cause HD.1
Common HD Models
- Cell models: primary striatal neurons, PC12, patient iPSC‑derived neurons, CRISPR‑edited isogenic lines
- Animal models: R6/1, R6/2, YAC128, BACHD mice
- 3D models: HD cortical/striatal organoids, 3D neurospheres, microfluidic HD‑on‑a‑chip
Service Contents
- Generation of isogenic HD cell lines and iPSC models
- 3D striatal/cortical organoid culture and maturation
- Mutant HTT aggregation, neurodegeneration, and electrophysiological analysis
- Behavioral and pathological assessment in HD mouse models
- Drug efficacy screening and pharmacodynamic evaluation
Applications
- Mechanistic studies of mutant HTT toxicity and neurodegeneration
- High-throughput drug screening and neuroprotective compound validation
- Gene therapy (CRISPR, antisense oligonucleotides) testing
- Biomarker discovery and preclinical therapeutic development
Workflow
To initiate our specialized modeling service, clients typically provide:
- Specific Genetic Parameters: Details on target CAG repeat lengths or specific HTT gene mutations of interest.
- Biological Starting Materials: Either cryopreserved patient fibroblasts/monocytes for reprogramming or established iPSC lines.
- Therapeutic Candidate Specs: Information on the modality (e.g., AAV vector, antisense oligonucleotide, or small molecule) to be tested.
What We Can Offer
At Creative Biolabs, we recognize that every neurodegeneration project has unique biological requirements. We offer a high-capacity, precision-driven platform for Huntington's Disease Modeling that is fully customizable to your specific research goals.
Proprietary hiPSC-MSN Platform
Optimized codon usage and directed differentiation protocols to ensure high-purity Medium Spiny Neuron populations.
Large-Scale Organoid Production
Capability to generate thousands of standardized 3D striatal organoids for high-throughput phenotypic screening.
Customized Genome Editing
Expert CRISPR-Cas9 services to create isogenic pairs or introduce specific rare variants beyond standard CAG expansions.
Advanced AAV Customization
Design and production of rAAV vectors (AAV5, AAV9, AAV-PHP.B) with tissue-specific promoters and miR-451 backbone optimization.
Rigorous Quality Control
Every model undergoes strict validation, including genotype-phenotype correlation, single-nucleus RNAseq, and electrophysiological benchmarking.
End-to-End Documentation
Full traceability of cell line origin and processing, assessed and approved by our internal Quality Assurance team.
Flexible Experimental Design
We run assays in batch or continuous longitudinal modes to capture disease progression over time.
Experience the Creative Biolabs Advantage - Get a Quote Today →
Customer Reviews
FAQs
Q: How do you ensure the maturity of the iPSC-derived MSNs?
A: We utilize long-term maturation protocols and MEA electrophysiology to confirm marker expression (DARPP-32+) and functional firing patterns.
Q: Can your models test both viral and non-viral delivery systems?
A: Yes. Our 3D organoid and BBB-on-a-chip models are designed to evaluate AAVs, LNPs, and antisense oligonucleotides.
Q: Do you offer isogenic control lines?
A: Yes. We use CRISPR-Cas9 to create genetically identical control lines differing only by the CAG repeat length.
Q: How do you handle the potential for off-target effects in gene silencing?
A: We utilize the latest pri-miR-451 backbone technology, which eliminates passenger-strand production.
Q: Is it possible to model the interaction between neurons and glia?
A: Yes, our 3D organoid models include regionally specified astrocytes to study the holistic tissue environment.
Creative Biolabs offers an end-to-end solution for HD research, encompassing viral vector design, human-centric disease modeling, and functional integration assays. Whether you are developing gene-silencing miRNAs or regenerative cell therapies, our platform provides the biological accuracy required for modern drug discovery.
Contact Our Team for More Information and to Discuss Your Project →
Reference
- Gavgani, Pedram Moeini, and Mario García-Domínguez. "Revolutionizing Huntington's Disease Treatment: Breakthroughs in AAV-Mediated Gene Therapy." Cells 14.19 (2025): 1514. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cells14191514.
For Research Use Only. Not For Clinical Use.